Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Total Current Liabilities data on file, last reported at $62.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 6.19% year-over-year to $62.6 million in Q1 2026; TTM through Mar 2026 was $62.6 million, a 6.19% increase from a year earlier, with the FY2025 full-year figure at $83.2 million, up 22.79% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $62.6 million, down from $83.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for KYMR reached as high as $91.1 million in Q3 2022 and fell as low as $54.6 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $71.8 million across 5 years, with a median of $67.8 million in 2024.
• Across the five-year window, Total Current Liabilities slumped 37.6% in 2023 and surged 40.87% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $71.3 million in 2022, then climbed by 20.11% to $85.7 million in 2023, then dropped by 20.92% to $67.8 million in 2024, then grew by 22.79% to $83.2 million in 2025, then dropped by 24.72% to $62.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $62.6 million in Q1 2026, $83.2 million in Q4 2025, and $71.6 million in Q3 2025.